In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering.
A potential single-course treatment in which an infusion of guide RNA and mRNA encoding a CRISPR adenine base editor-encapsulated within a GalNAc-lipid nanoparticle-leads to durable, liver-selective inactivation of angiopoietin-like 3 (ANGPTL3), a known driver of increased LDL-C and triglyceride concentrations is descr...